Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jul 27:6:30266.
doi: 10.1038/srep30266.

Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score

Yu-Tzu Chang  1   2 , Jing-Shiang Hwang  3 , Shih-Yuan Hung  4 , Min-Sung Tsai  5 , Jia-Ling Wu  2 , Junne-Ming Sung  2 , Jung-Der Wang  2   6   7
Affiliations
Comparative Study

Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score

Yu-Tzu Chang et al. Sci Rep. .

Abstract

Although treatment for the dialysis population is resource intensive, a cost-effectiveness analysis comparing hemodialysis (HD) and peritoneal dialysis (PD) by matched pairs is still lacking. After matching for clinical characteristics and propensity scores, we identified 4,285 pairs of incident HD and PD patients from a Taiwanese national cohort during 1998-2010. Survival and healthcare expenditure were calculated by data of 14-year follow-up and subsequently extrapolated to lifetime estimates under the assumption of constant excess hazard. We performed a cross-sectional EQ-5D survey on 179 matched pairs of prevalent HD and PD patients of varying dialysis vintages from 12 dialysis units. The product of survival probability and the mean utility value at each time point (dialysis vintage) were summed up throughout lifetime to obtain the quality-adjusted life expectancy (QALE). The results revealed the estimated life expectancy between HD and PD were nearly equal (19.11 versus 19.08 years). The QALE's were also similar, whereas average lifetime healthcare costs were higher in HD than PD (237,795 versus 204,442 USD) and the cost-effectiveness ratios for PD and HD were 13,681 and 16,643 USD per quality-adjusted life year, respectively. In conclusion, PD is more cost-effective than HD, of which the major determinants were the costs for the dialysis modality and its associated complications.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram of establishing the study cohorts and cross-sectional samples followed by matching on clinical characteristics and propensity scores for patients under hemodialysis (HD) and peritoneal dialysis (PD) to estimate quality-adjusted life expectancy (QALE) and lifetime costs.
Abbreviation: ESRD: end-stage renal disease; QALE: quality-adjusted life expectancy; QALY: quality-adjusted life year.
Figure 2
Figure 2. Estimation of quality-adjusted life expectancy (QALE) for patients under hemodialysis (HD) and peritoneal dialysis (PD).
Lifetime survival curves of HD and PD were depicted in the black and red lines, respectively. The QALE was estimated by summarizing the total area under the survival curve.
Figure 3
Figure 3
(a) Average monthly costs for inpatient and outpatient healthcare expenditures and (b) monthly proportions of outpatient costs within total healthcare expenditures of patients selected from 1:1 matched hemodialysis (HD) and peritoneal dialysis (PD) during the follow-up period.
See this image and copyright information in PMC

References

    1. Meguid El Nahas A. & Bello A. K. Chronic kidney disease: the global challenge. Lancet 365, 331–340, 10.1016/S0140-6736(05)17789-7 (2005). - DOI - PubMed
    1. Klarenbach S. W., Tonelli M., Chui B. & Manns B. J. Economic evaluation of dialysis therapies. Nat. Rev. Nephrol. 10, 644–652, 10.1038/nrneph.2014.145 (2014). - DOI - PubMed
    1. US Renal Data System. USRDS 2014. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2014. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at: http://www.usrds.org/2014/view/Default.aspx (Accessed: 17 August 2015).
    1. Levey A. S. et al.. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247–259, 10.1038/sj.ki.5002343 (2007). - DOI - PubMed
    1. US Renal Data System. USRDS 2007. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2007. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at: http://http://www.usrds.org/atlas07.aspx (Accessed: 17 August 2015).

Publication types

MeSH terms